U.S. Sen. Lamar Alexander (R-Tenn.) and Rep. Greg Walden (R-Ore.) asked for, and got, input from 340B stakeholders about how 340B could be improved. The comments will help frame the battle over 340B’s future and where the debate will be headed in 2021. | Source: Shutterstock
GOP Committee Leaders Asked for and Got 340B Reform Ideas. What Happens Now?
Pharmaceutical manufacturers told two Republican congressional committee leaders late last week that the 340B program isn’t a safety net for vulnerable patients; it’s just a money maker for vested interests, they said, and Congress should fix it.
Health systems and hospitals told the leaders 340B works well. They say Congress should press the executive branch to take a harder line against drug manufacturers that evade 340B requirements.
.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
×